SGLT2 inhibitor is kidney protective, even if eGFR <30

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

NEW EPISODE
ns-MRAs and eGFR Slope: The Kidney Perspective
ns-MRAs and eGFR Slope: The Kidney Perspective
MinuteCE®
ns-MRAs and eGFR Slope: The Kidney Perspective
1.25 program credits
- Csaba P. Kovesdy, MD
- Finnian R. Mc Causland, MD
1.25 program credits
Perspectives on CKM syndrome
Perspectives on CKM syndrome
AHA 2024
Perspectives on CKM syndrome
- Javed Butler, MD
A multidisciplinary clinical dialogue: Optimizing long-term goals: practical approaches to novel potassium binder use in cardiorenal care
A multidisciplinary clinical dialogue: Optimizing long-term goals: practical approaches to novel potassium binder use in cardiorenal care
MinuteCE®
A multidisciplinary clinical dialogue: Optimizing long-term goals: practical approaches to novel potassium binder use in cardiorenal care
0.75 program credits
- James Burton, DM, FRCP
- Aaron Wong, MD
0.75 program credits
Challenges of managing hyperkalemia in HF patients with CKD while maintaining RAAS inhibitor therapy
Challenges of managing hyperkalemia in HF patients with CKD while maintaining RAAS inhibitor therapy
MinuteCE®
Challenges of managing hyperkalemia in HF patients with CKD while maintaining RAAS inhibitor therapy
0.75 program credits
- Gianluigi Savarese, MD
0.75 program credits